Inclusion criteria:

          -  Locally advanced or metastatic solid malignant tumor disease for which, in the
             judgement of the investigator, no standard alternative therapy is available.

          -  Inclusion is likely to be expressing CEACAM5.

          -  At least 6 x 5 μm slides from formalin-fixed paraffin-embedded (FFPE) archival tissue
             should be available for retrospective central evaluation of CEACAM5 expression.

          -  Patient understands and has signed the Written Informed Consent form and is willing
             and able to comply with the requirements of the trial.

        Exclusion criteria:

          -  Patient less than 20 years old.

          -  Eastern Cooperative Oncology Group (ECOG) performance status (PS) ≥2.

          -  Life expectancy <12 weeks.

          -  Known or symptomatic brain metastasis (other than totally resected or previously
             irradiated and non-progressive/relapsing) or lepto-meningeal carcinomatosis.

          -  Female patients of childbearing potential and male patients with female partners of
             childbearing potential who do not agree to use accepted and effective method of
             contraception during the study treatment period and for 6 months following
             discontinuation of IMP.

          -  Significant concomitant illnesses, including all severe medical conditions which, in
             the opinion of the Investigator or Sponsor, would impair the patient's participation
             in the study or interpretation of the results.

          -  Prior therapy targeting CEACAM5.

          -  Prior maytansinoid treatments (maytansinoid derivative 1 [DM1] or maytansinoid
             derivative 4 [DM4] antibody drug conjugates).

          -  Previous history and or unresolved corneal disorders.

          -  Medical conditions requiring concomitant administration of medications with narrow
             therapeutic window, metabolized by cytochrome P450 (CYP) and for which a dose
             reduction cannot be considered.

          -  Medical conditions requiring concomitant administration of strong CYP3A inhibitor,
             unless it can be discontinued at least 2 weeks before first administration of
             SAR408701.

        The above information is not intended to contain all considerations relevant to a patient's
        potential participation in a clinical trial.